SCHEMBL2907694

SCHEMBL2907694

COc1cc2nc(CO)ccc2c(OC)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.43
PDE3B Q13370 3/20 0.43
PDE3A Q14432 3/20 0.43
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
TUBB4A P04350 3/20 0.39
TUBB P07437 3/20 0.39
TUBA3C P0DPH7 3/20 0.39
TUBA1B P68363 3/20 0.39
TUBA4A P68366 3/20 0.39
TUBB4B P68371 3/20 0.39
TUBB3 Q13509 3/20 0.39
TUBB2A Q13885 3/20 0.39
TUBB8 Q3ZCM7 3/20 0.39
TUBA3E Q6PEY2 3/20 0.39
TUBA1A Q71U36 3/20 0.39
TUBA1C Q9BQE3 3/20 0.39
TUBB6 Q9BUF5 3/20 0.39
TUBB2B Q9BVA1 3/20 0.39
TUBB1 Q9H4B7 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7837160 0.86 PDE3A (0.47) MAOAPDE3BPDE3APDGFRBPDGFRA
SCHEMBL2905838 0.84 MAOA (0.43) MAOAPDE3BPDE3APDGFRBPDGFRA
SCHEMBL13792058 0.81 MAOA (0.40) MAOAPDE3BPDE3APDGFRBPDGFRA
SCHEMBL2908611 0.80 KDM4E (0.40) MAOAPDE3BPDE3AKDM4E
SCHEMBL2909338 0.77 MAOA (0.47) MAOAPDE3BPDE3APDGFRBPDGFRA
SCHEMBL2909778 0.76 KDM4E (0.45) PDE3BPDE3AKDM4EPSMB5POLB
SCHEMBL27518751 0.76 MAOA (0.46) MAOAPDE3BPDE3APDGFRBPDGFRA
SCHEMBL1337795 0.76 MAOA (0.46) MAOAPDE3BPDE3APDGFRBPDGFRA
SCHEMBL28231525 0.74 ALOX15 (0.54) MAOAPDE3BPDE3AKDM4E
SCHEMBL1337297 0.72 PDE3B (0.46) MAOAPDE3BPDE3APDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400510-B1 CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS KOWA CO (JP) 2010-08-18 EP disclosed
US-7135473-B2 Cyclic diamine compound with condensed-ring groups KOWA CO., LTD. (JP) 2006-11-14 US disclosed
US-20040058913-A1 Cyclic diamine compound with condensed-ring groups KOWA CO., LTD. (JP) 2004-03-25 US disclosed
EP-1400510-A1 CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6632810-B2 Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation KOWA CO., LTD. (JP) 2003-10-14 US disclosed
US-20030060461-A1 Cyclic diamine compound with condensed-ring groups KOWA CO., LTD. (JP) 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058913-A1 Cyclic diamine compound with condensed-ring groups HRH4, HRH3, HRH1 MAOA 1802/4885PDE3B 2488/4885PDE3A 2720/4885
US-20030060461-A1 Cyclic diamine compound with condensed-ring groups HRH4, HRH3, HRH1 MAOA 1802/4885PDE3B 2488/4885PDE3A 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.